CKD Bio종근당바이오
063160 · KOSPI · ₩063160 · 종근당바이오
₩12,350▼ ₩30 (0.24%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 10.9% | 18.0% | 20.9% | 5.0% | 11.3% | 9.3% |
| Operating margin | −5.1% | 2.3% | 6.4% | −12.6% | −8.4% | −6.2% |
| Net margin | −4.9% | −1.8% | 5.1% | −15.1% | −9.8% | −7.4% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −1.2% | −6.8% | +7.1% | +2.8% | +9.8% | — |
| Operating income growth | −323.8% | −67.1% | +154.4% | −53.2% | −49.1% | — |
| Net income growth | −170.5% | −133.2% | +136.0% | −59.1% | −45.2% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −6.3% | −2.2% | 6.9% | −17.9% | −9.9% | −6.5% |
| Return on assets | −2.6% | −1.0% | 3.0% | −8.0% | −5.0% | −3.5% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 145.1% | 136.0% | 117.2% | 138.8% | 111.3% | 85.5% |
| Net debt to equity | 121.9% | 111.3% | 98.4% | 115.0% | 89.3% | 64.3% |
| Current ratio | 105.9% | 89.6% | 127.1% | 113.3% | 151.6% | 233.3% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: CKD Bio / 종근당바이오 / 063160 / KRX:063160
Source: KRX statistical information